Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Hironobu Goto, Taro Oshikiri, Takashi Kato, Yoshiaki Nagatani, Yohei Funakoshi, Yasufumi Koterazawa, Ryuichiro Sawada, Hitoshi Harada, Naoki Urakawa, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Takeru Matsuda, Hironobu Minami, Yoshihiro Kakeji
BACKGROUND: In Japan, preoperative adjuvant chemotherapy followed by surgical resection is the standard treatment for patients with locally advanced esophageal squamous cell carcinoma. However, the risk of recurrence after surgical resection remains high. Although a randomized controlled trial evaluating the efficacy of nivolumab, a fully human monoclonal anti-programmed death 1 antibody, as postoperative adjuvant therapy after neoadjuvant chemoradiotherapy and surgery established its superior efficacy as adjuvant therapy, the efficacy for patients who received preoperative adjuvant chemotherapy has not been demonstrated...
2024: PloS One
#2
REVIEW
Sharona B Ross, Jesse Popover, Iswanto Sucandy, Maria Christodoulou, Tara M Pattilachan, Alexander S Rosemurgy
Pancreatic adenocarcinoma, increasingly diagnosed in the United States, has a disheartening initial resection rate of 15%. Neoadjuvant therapy, particularly FOLFIRINOX and gemcitabine-based regimens, is gaining favor for its potential to improve resectability rates and achieving microscopically negative margins (R0) in borderline resectable cases, marked by intricate arterial or venous involvement. Despite surgery being the sole curative approach, actual benefit of neoadjuvant therapy remains debatable. This study scrutinizes current literature on oncological outcomes post-resection of borderline resectable pancreatic cancer...
April 18, 2024: American Surgeon
#3
JOURNAL ARTICLE
Francesco Massari, Matteo Santoni, Hideki Takeshita, Yohei Okada, Jose Carlos Tapia, Umberto Basso, Marco Maruzzo, Sarah Scagliarini, Thomas Büttner, Giuseppe Fornarini, Zin W Myint, Luca Galli, Vinicius Carrera Souza, Renate Pichler, Ugo De Giorgi, Nathalia Gandur, Elaine T Lam, Danielle Gilbert, Lazar Popovic, Enrique Grande, Giulia Mammone, Rossana Berardi, Simon J Crabb, Robert Kemp, Javier Molina-Cerrillo, Marcelo Freitas, Murilo Luz, Roberto Iacovelli, Fabio Calabrò, Deniz Tural, Francesco Atzori, Zsófia Küronya, Rita Chiari, Saul Campos, Orazio Caffo, André P Fay, Jakub Kucharz, Paolo Andrea Zucali, José Augusto Rinck, Annalisa Zeppellini, Diogo Assed Bastos, Gaetano Aurilio, Augusto Mota, Karine Trindade, Cinzia Ortega, Juan Pablo Sade, Mimma Rizzo, Ondřej Fiala, Nuno Vau, Patrizia Giannatempo, Allan Barillas, Fernando Sabino M Monteiro, Breno Dauster, Alessia Mennitto, Lucas Nogueira, Roni de Carvalho Fernandes, Emmanuel Seront, Luís Garcia Aceituno, Francesco Grillone, Hernan Javier Cutuli, Mauricio Fernandez, Maria Bassanelli, Ray Manneh Kopp, Giandomenico Roviello, Halima Abahssain, Giuseppe Procopio, Michele Milella, Jindrich Kopecky, Angelo Martignetti, Carlo Messina, Manuel Caitano, Eva Inman, Ravindran Kanesvaran, Daniel Herchhorn, Daniele Santini, Aristotelis Bamias, Renato Bisonni, Alessandra Mosca, Franco Morelli, Fernando Maluf, Andrey Soares, Fernando Nunes, Alvaro Pinto, Anca Zgura, Lorena Incorvaia, Jawaher Ansari, Ignacio Ortego Zabalza, Johannes Landmesser, Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, Matteo Rosellini, Giulia Sorgentoni, Nicola Battelli, Sebastiano Buti, Camillo Porta, Joaquim Bellmunt
BACKGROUND: Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. PATIENTS AND METHODS: Medical records of patients with documented metastatic UC treated by pembrolizumab as second-line therapy were retrospectively collected from 88 institutions in 23 countries...
April 18, 2024: Cancer Immunology, Immunotherapy: CII
#4
JOURNAL ARTICLE
María de Armas Conde, Carmen Díaz-López, Vanessa Concepción-Martín, María Del Pilar Borque-Barrera
BACKGROUND AND STUDY AIMS: Upper gastrointestinal tract (UGT) leaks are associated with severe morbidity and mortality. Endoluminal vacuum (EVAC) therapy is a promising approach for repairing effectively these defects. Our study describes the results obtained from a series of cases treated with EVAC for the management of esophageal anastomotic (EA) leak following esophagectomy for cancer, gastroenteric (GE) anastomoses leak after bariatric surgery and esophageal perforation (EP). PATIENTS AND METHODS: We retrospectively analyzed ten patients who had an EA and GE anastomoses leaks and EP treated with EVAC...
April 18, 2024: Revista Española de Enfermedades Digestivas
#5
JOURNAL ARTICLE
Mohammed Al-Zubaidi, Katherine Ong, Pravin Viswambaram, Haider Bangash, Glenn Boardman, Steve P McCombie, Oliver Oey, Nicole Swarbrick, Andrew Redfern, Jeremy Ong, Richard Gauci, Ronny Low, Dickon Hayne
OBJECTIVES: We aim to assess the clinical value of 18 F-fluorodeoxyglucose positron (18 F-FDG-PET) scan in detecting nodal and distant metastasis compared with computed tomography (CT) scan in patients with urothelial carcinoma or bladder cancer, aiming to improve staging accuracy and thereby better prognosticate and determine therapy. METHODS: A retrospective review of 75 patients with invasive bladder cancer (≥T1) who were staged with both CT and 18 F-FDG-PET within an 8-week interval was performed for the period between 2015 and 2020...
April 2024: BJUI compass
#6
MULTICENTER STUDY
Soong June Bae, Jung Whan Chun, Sae Byul Lee, Jai Min Ryu, Seok Jin Nam, Joon Jeong, Hyung Seok Park, Sung Gwe Ahn
BACKGROUND: This study investigated the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST) in patients with initially high nodal burden. METHODS: In the multicenter retrospective cohort, 388 individuals with cN1-3 breast cancer who underwent NAST and had SLNB followed by completion axillary lymph node dissection were included. In an external validation cohort, 267 patients with HER2+ or triple-negative breast cancer (TNBC) meeting similar inclusion criteria were included...
April 17, 2024: Breast Cancer Research: BCR
#7
JOURNAL ARTICLE
Yichen Wang, Wenhua Zhang, Lijun Chen, Jun Xie, Xuebin Zheng, Yan Jin, Qiang Zheng, Qianqian Xue, Bin Li, Chuan He, Haiquan Chen, Yuan Li
BACKGROUND: Neoadjuvant therapy followed by surgery has become the standard of care for locally advanced esophageal squamous cell carcinoma (ESCC) and accurate pathological response assessment is critical to assess the therapeutic efficacy. However, it can be laborious and inconsistency between different observers may occur. Hence, we aim to develop an interpretable deep-learning model for efficient pathological response assessment following neoadjuvant therapy in ESCC. METHODS: This retrospective study analyzed 337 ESCC resection specimens from 2020-2021 at the Pudong-Branch (Cohort 1) and 114 from 2021-2022 at the Puxi-Branch (External Cohort 2) of Fudan University Shanghai Cancer Center...
April 17, 2024: Biological Procedures Online
#8
JOURNAL ARTICLE
C Sanghera, D P McClurg, C M Jones
BACKGROUND AND AIM: There has been limited progress made in improving the suboptimal outcomes delivered by conventionally fractionated radiotherapy (RT) for oesophageal adenocarcinoma (OAC) and squamous cell carcinoma (OSCC). A greater biological effect may be achieved using hypofractionated RT (HFRT), though the toxicity, tolerability and efficacy of this approach in OAC and OSCC is uncertain. METHODS: A systematic literature review was carried out in accordance with Preferred Reporting Items for Systematic Reviews guidance...
March 18, 2024: Clinical Oncology: a Journal of the Royal College of Radiologists
#9
JOURNAL ARTICLE
Lucas Soares Gerbasi, Francisco Tustumi, Victor Edmond Seid, Sergio Eduardo Alonso Araujo
BACKGROUND AND OBJECTIVES: This study evaluates the Tri-Staple™ technology in colorectal anastomosis. METHODS: Patients who underwent rectosigmoidectomy between 2016 and 2022 were retrospectively evaluated and divided into two groups: EEA™ (EEA) or Tri-Staple™ (Tri-EEA). The groups were matched for age, sex, American Society of Anesthesiologists (ASA), and neoadjuvant radiotherapy using propensity score matching (PSM). RESULT: Three hundred and thirty-six patients were included (228 EEA; 108 Tri-EEA)...
April 17, 2024: Journal of Surgical Oncology
#10
JOURNAL ARTICLE
Robert C Walker, Jack Harrington, Stella P Breininger, Oliver Pickering, Samuel L Hill, Benjamin P Sharpe, Ben Grace, Ian Reddin, Rushda Rajak, Antigoni Manousopoulou, Spiros D Garbis, Zoë S Walters, Matthew J J Rose-Zerilli, Timothy J Underwood
No abstract text is available yet for this article.
April 3, 2024: British Journal of Surgery
#11
JOURNAL ARTICLE
Katsumasa Nakamura, Keiji Nihei, Yoshihiro Saito, Naoto Shikama, Shin-Ei Noda, Ryusuke Hara, Toshiyuki Imagumbai, Takashi Mizowaki, Takeshi Akiba, Etsuo Kunieda, Masanori Someya, Saiji Ohga, Jiro Kawamori, Takuyo Kozuka, Yosuke Ota, Koji Inaba, Takeshi Kodaira, Yoshiyuki Itoh, Kouta Funakoshi, Yoshikazu Kagami
BACKGROUND: The aim of this multi-institutional phase II study was to confirm the safety and the potential efficacy of moderately hypofractionated intensity-modulated radiotherapy (IMRT) with prostate-based image-guidance for Japanese patients. METHODS: Patients with low- or intermediate-risk localized prostate cancer were eligible. Patients with a part of high risk (having only one of the following factors, cT3a, 20 < PSA ≤ 30, or GS = 8 or 9) were also included...
April 17, 2024: International Journal of Clinical Oncology
#12
JOURNAL ARTICLE
Susan Aherne, Mark Donnelly, Éanna J Ryan, Matthew G Davey, Ben Creavin, Erinn McGrath, Aoife McCarthy, Robert Geraghty, David Gibbons, Iris Nagtegaal, Alessandro Lugli, Richard Kirsch, Sean T Martin, Desmond C Winter, Kieran Sheahan
BACKGROUND: Tumour budding (TB) is a marker of tumour aggressiveness which, when measured in rectal cancer resection specimens, predicts worse outcomes and response to neoadjuvant therapy. We investigated the utility of TB assessment in the setting of neoadjuvant treatment. METHODS AND RESULTS: A single-centre, retrospective cohort study was conducted. TB was assessed using the hot-spot International Tumour Budding Consortium (ITBCC) method and classified by the revised ITBCC criteria...
April 17, 2024: Histopathology
#13
REVIEW
Current status of preoperative endoscopic biliary drainage for distal and hilar biliary obstruction.
Hirotoshi Ishiwatari, Junya Sato, Hiroki Sakamoto, Takuya Doi, Hiroyuki Ono
The purpose of preoperative biliary drainage (PBD) is to reduce complications during the perioperative period. The extrahepatic bile duct comprises distal and hilar bile ducts and assessing the need for PBD must be considered separately for each duct, as surgical procedures and morbidities vary. The representative disease-causing distal bile duct obstruction is pancreatic cancer. A randomized controlled trial has revealed that PBD carries the risk of recurrent cholangitis and pancreatitis before surgery, thus eliminating the need for PBD when early surgery is feasible...
April 17, 2024: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
#14
JOURNAL ARTICLE
Kamil Nurczyk, Norbert Nowak, Tomasz Orczykowski, Paweł Bojar, Dariusz Duma, Renata Gieroba, Grzegorz Wallner, Tomasz Skoczylas
<b><br>Introduction:</b> Neoadjuvant chemotherapy (NAC) is a part of the current standard of care in a locally advanced gastric adenocarcinoma (GA) and esophagogastric junction adenocarcinoma (EGJA), but only patients with good pathomorphological response (pR) to NAC benefit from prolonged overall survival.</br> <b><br>Aim:</b> The study aims to evaluate ApoA-I and ApoB as candidate pre-treatment biomarkers of pR to NAC in patients with GA and EGJA...
September 20, 2023: Polski Przeglad Chirurgiczny
#15
JOURNAL ARTICLE
Luise Rupp, Ina Dietsche, Maximilian Kießler, Ulrich Sommer, Alexander Muckenhuber, Katja Steiger, Casper W F van Eijck, Leonard Richter, Rouzanna Istvanffy, Carsten Jäger, Helmut Friess, Casper H J van Eijck, Ihsan Ekin Demir, Carmen Mota Reyes, Marc Schmitz
Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at advanced stages and associated with early distant metastasis and poor survival. Besides clinical factors, the tumor microenvironment (TME) emerged as a crucial determinant of patient survival and therapy response in many tumors, including PDAC. Thus, the presence of tumor-infiltrating lymphocytes and the formation of tertiary lymphoid structures (TLS) is associated with longer survival in PDAC. Although neoadjuvant therapy (NeoTx) has improved the management of locally advanced tumors, detailed insight into its effect on various TME components is limited...
2024: Frontiers in Immunology
#16
Chengyu Hu, Bixian Luo, Bo Hong, Mingqi Zhang, Zelai Wu, Xiuliang Zhu, Fengming Luan, Yi Huang, Weihua Gong
Paragangliomas (PGLs) are rare neuroendocrine tumors which overproduce catecholamines (CAs). They are extra-adrenal, catecholamine-secreting tumors occurring outside the adrenal glands. Gastric PGLs originating from extra-adrenal paraganglia are exceptionally rare, and their presentation in geriatric patients further adds to the complexity of diagnosis and management. A 72-year-old male patient presented with enduring left upper abdominal pain and anemia persisting for over a year, and hypertension for six months...
2024: Frontiers in Oncology
#17
JOURNAL ARTICLE
Melina Boutin, Tharani Krishnan, Maria Safro, Jenny Yang, Helia Jafari, Janine M Davies, Sharlene Gill
BACKGROUND: Complete resection followed by adjuvant chemotherapy is the gold standard for patients with localized cholangiocarcinoma (CC) or gallbladder cancer (GBC). However, this is not always feasible, and recurrence rates remain high. OBJECTIVES: To understand the real-world proportions and reason for treatment failure in resected biliary tract cancers. DESIGN AND METHODS: We performed a retrospective population-based review of patients with GBC or CC [intrahepatic (IHCC) or extrahepatic (EHCC)] resected between 2005 and 2019 using the BC Cancer provincial database...
2024: Therapeutic Advances in Medical Oncology
#18
JOURNAL ARTICLE
Betty Y Zhang, Ashley R Wilson-Smith, Elizabeth A Connolly, Madeleine C Strach, Nathan Ussher, Tristan Yan, Vivek A Bhadri
BACKGROUND: Extrapleural pneumonectomy (EPP) is a complex surgical procedure involving en-bloc resection of the parietal and visceral pleura, lung, pericardium, and ipsilateral diaphragm. Small case series of pleural-based sarcoma of predominantly pediatric patients suggest EPP may be a life-prolonging surgical option. We aimed to describe the characteristics and outcomes of adults who underwent EPP at a specialized sarcoma center. METHODS: Clinicopathologic variables, surgical details, and follow-up information were extracted for patients undergoing EPP for pleural-based sarcoma between August 2017 and December 2020...
April 2024: Cancer reports
#19
JOURNAL ARTICLE
Misbah Younus Soomro, Saqib Raza Khan, Hafiz Muhammad, Sujjawal Ahmad, Nawazish Zehra, Insia Ali, Mirza Rameez Samar, Arif Hameed, Munira Moosajee, Yasmin Abdul Rashid
BACKGROUND: Rectal cancer treatment has transformed in recent years, with neoadjuvant treatment (NT) and total neoadjuvant treatment (TNT) aiming to enhance pathological responses. This pioneering study in our country delves into rectal cancer management, offering crucial insights by examining pathological outcomes in patients treated with the NT and TNT approach, shaping the evolving landscape. METHODS: In this retrospective-cohort study spanning January 2017 to December 2022 at a tertiary care hospital in Pakistan, ethical approval was obtained to examine outcomes of two treatments...
April 16, 2024: BMC Cancer
#20
JOURNAL ARTICLE
Zhongchao Li, Jing Liu, Bo Zhang, Jinbo Yue, Xuetao Shi, Kai Cui, Zhaogang Liu, Zhibin Chang, Zhicheng Sun, Mingming Li, Yue Yang, Zhao Ma, Lei Li, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Lei Zhao
Notable-HCC (NCT05185531) is a phase 1b trial, aiming to evaluate the safety and preliminary effectiveness of neoadjuvant PD-1 blockade plus stereotactic body radiotherapy (SBRT) in early-stage resectable hepatocellular carcinoma (HCC). Twenty patients with HCC of BCLC stage 0-A received 3 <mml:math xmlns:mml="https://www.w3.org/1998/Math/MathML"><mml:mo>×</mml:mo></mml:math> Gy SBRT and two cycles of tislelizumab, an anti-PD-1 monoclonal antibody before the curative HCC resection...
April 16, 2024: Nature Communications
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
